JP2022515152A5 - - Google Patents
Info
- Publication number
- JP2022515152A5 JP2022515152A5 JP2021535665A JP2021535665A JP2022515152A5 JP 2022515152 A5 JP2022515152 A5 JP 2022515152A5 JP 2021535665 A JP2021535665 A JP 2021535665A JP 2021535665 A JP2021535665 A JP 2021535665A JP 2022515152 A5 JP2022515152 A5 JP 2022515152A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- recombinant protein
- protein according
- chain variable
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024192700A JP2025032075A (ja) | 2018-12-19 | 2024-11-01 | Baff-r二重特異性t細胞エンゲージャー抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782317P | 2018-12-19 | 2018-12-19 | |
| US62/782,317 | 2018-12-19 | ||
| PCT/US2019/067563 WO2020132291A1 (en) | 2018-12-19 | 2019-12-19 | Baff-r bispecific t-cell engager antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024192700A Division JP2025032075A (ja) | 2018-12-19 | 2024-11-01 | Baff-r二重特異性t細胞エンゲージャー抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022515152A JP2022515152A (ja) | 2022-02-17 |
| JP2022515152A5 true JP2022515152A5 (cg-RX-API-DMAC7.html) | 2022-12-21 |
Family
ID=71098268
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535665A Pending JP2022515152A (ja) | 2018-12-19 | 2019-12-19 | Baff-r二重特異性t細胞エンゲージャー抗体 |
| JP2024192700A Pending JP2025032075A (ja) | 2018-12-19 | 2024-11-01 | Baff-r二重特異性t細胞エンゲージャー抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024192700A Pending JP2025032075A (ja) | 2018-12-19 | 2024-11-01 | Baff-r二重特異性t細胞エンゲージャー抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200199232A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3897720A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022515152A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210104816A (cg-RX-API-DMAC7.html) |
| CN (2) | CN113412124A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019404282A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3123599A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020132291A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| CN116997573A (zh) * | 2020-10-15 | 2023-11-03 | 佳努克斯治疗公司 | 靶向psma和cd3的抗体及其用途 |
| US20240034807A1 (en) * | 2021-02-16 | 2024-02-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Molecules that bind to mesothelin polypeptides |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| JP2025523874A (ja) * | 2022-07-19 | 2025-07-25 | ノバルティス アーゲー | Baff又はbaff受容体阻害抗体でのaihaの治療 |
| WO2024074145A1 (zh) * | 2022-10-08 | 2024-04-11 | 盛禾(中国)生物制药有限公司 | 一种结合baffr和cd3的双特异性抗体及其应用 |
| CN121464157A (zh) * | 2023-02-28 | 2026-02-03 | 梅约医学教育与研究基金会 | 结合至b细胞活化因子受体多肽的分子 |
| WO2025221674A1 (en) * | 2024-04-15 | 2025-10-23 | Eli Lilly And Company | Baffr x cd3 bispecific antibodies and methods of use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4733635B2 (ja) * | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗cd19抗体 |
| SMT201800335T1 (it) * | 2012-11-06 | 2018-09-13 | Bayer Pharma AG | Formulazione di attivatori bispecifici per linfociti t (bite) |
| EP2948475A2 (en) * | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| ES2980787T3 (es) * | 2014-07-31 | 2024-10-03 | Amgen Res Munich Gmbh | Constructo de anticuerpo de cadena sencilla biespecífico con distribución tisular potenciada |
| WO2016094873A2 (en) * | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| EP3778640A1 (en) * | 2015-05-01 | 2021-02-17 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
| EP3310811B1 (en) * | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| TWI811023B (zh) * | 2015-08-17 | 2023-08-01 | 美商健生生物科技公司 | 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途 |
| UA126657C2 (uk) * | 2016-02-03 | 2023-01-11 | Емджен Рісерч (Мюнік) Ґмбг | ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font> |
| US11136405B2 (en) * | 2016-06-06 | 2021-10-05 | Board Of Regents, The Unviersity Of Texas System | BAFF-R antibodies and uses thereof |
| EP3464371B1 (en) * | 2016-06-06 | 2026-07-29 | City of Hope | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof |
| AU2017337073A1 (en) * | 2016-09-30 | 2019-04-18 | Baylor College Of Medicine | Antibody based gene therapy with tissue-directed expression |
| KR20210129125A (ko) * | 2019-02-20 | 2021-10-27 | 시티 오브 호프 | Baff-r/cd19 표적화된 키메라 항원 수용체-변형된 t 세포 및 그의 용도 |
-
2019
- 2019-12-19 JP JP2021535665A patent/JP2022515152A/ja active Pending
- 2019-12-19 AU AU2019404282A patent/AU2019404282A1/en active Pending
- 2019-12-19 WO PCT/US2019/067563 patent/WO2020132291A1/en not_active Ceased
- 2019-12-19 CN CN201980089634.XA patent/CN113412124A/zh active Pending
- 2019-12-19 CA CA3123599A patent/CA3123599A1/en active Pending
- 2019-12-19 US US16/721,485 patent/US20200199232A1/en not_active Abandoned
- 2019-12-19 US US17/414,867 patent/US20220056132A1/en not_active Abandoned
- 2019-12-19 KR KR1020217022324A patent/KR20210104816A/ko not_active Ceased
- 2019-12-19 CN CN202511607565.0A patent/CN121405815A/zh active Pending
- 2019-12-19 EP EP19900284.1A patent/EP3897720A4/en active Pending
-
2024
- 2024-11-01 JP JP2024192700A patent/JP2025032075A/ja active Pending